New senior vice-president at Cellectis
This article was originally published in Scrip
Cellectis, the French specialist in genome engineering specialist, has appointed Dr Mathieu Simon to the position of senior vice-president. He will be in charge of developing therapeutic and new commercial activities, including launching innovative products. Dr Simon was previously senior vice-president of pharma global operations for Groupe Pierre Fabre Medicament, and has also worked for Wyeth in the US and France.
You may also be interested in...
Positive Phase II data for Aptinyx’s novel NMDA receptor modulator are strong enough to take the product into a pivotal study in this difficult-to-treat area.
Orchard Therapeutics is on the cusp of the first approval for its ex vivo gene therapy, Libmeldy, for metachromatic leukodystrophy.
Gilead/Kite’s second CAR-T product is given the go-ahead for approval by the CHMP for mantle cell lymphoma.